Care Process Use Linked to Reduced S. Aureus Mortality

Share this content:
Care Process Use Linked to Reduced <i>S. Aureus</i> Mortality
Care Process Use Linked to Reduced S. Aureus Mortality

WEDNESDAY, Sept. 6, 2017 (HealthDay News) -- Use of evidence-based care processes in routine care for Staphylococcus aureus bacteremia is associated with reduced mortality, according to a study published online Sept. 5 in JAMA Internal Medicine.

Michihiko Goto, M.D., from the Iowa City Veterans Affairs Health Care System in Iowa, and colleagues examined the correlation between evidence-based care processes in routine care for S. aureus bacteremia and mortality in a retrospective observational cohort study. Data were included for 36,868 patients in 124 hospitals.

The researchers found that from 2003 to 2014 there was a decrease in risk-adjusted mortality from 23.5 to 18.2 percent. During the same period, the rates of appropriate antibiotic prescribing increased from 66.4 to 78.9 percent, echocardiography increased from 33.8 to 72.8 percent, and infectious disease (ID) specialist consultation increased from 37.4 to 68 percent. Receipt of care processes correlated with reductions in mortality, with adjusted odds ratios of 0.74 for appropriate antibiotics, 0.73 for echocardiography, and 0.61 for ID consultation after adjustment for patient characteristics, cohort year, and other care processes. A progressive decrease in mortality was seen as the number of care processes increased (adjusted odds ratio for all three versus no care process, 0.33). Use of these care processes accounted for an estimated 57.3 percent of the decrease in mortality.

"Increasing application of these care processes may improve survival among patients with S. aureus bacteremia in routine health care settings," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »